MedTrace Logo

Non-inferiority Study Comparing Firehawk Stent With Abbott Xience Family Stent (TARGET-AC)

NCT02520180 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1653

Last updated 2023-10-23

No results posted yet for this study

Summary

Purpose The TARGET All comers trial is a prospective, multicenter, randomized, two-arm, non-inferiority, open-label study with 1656 patients at 20 centers in Europe. The study is a "real world, all comers" study.

Conditions

Interventions

DEVICE

Firehawk™ stent system

MicroPort Firehawk™ biodegradable polymer rapamycin target eluting stent

DEVICE

Abbott Xience family Everolimus-Eluting Stent

Abbott Xience family Everolimus-Eluting Stent

Sponsors & Collaborators

  • Shanghai MicroPort Medical (Group) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • William Wijns, MD, PhD · VZW Cardiovascular Research Center Aalst

  • Andreas Baumbach, MD · Bristol Heart Institute/University Hospitals Bristol NHS Foundation Trust,UK

  • Alexandra Lansky, MD · Yale Cardiovascular Research Group,USA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2016-10-31
Completion
2022-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02520180 on ClinicalTrials.gov